TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27159993

Group type: EXPERIMENTAL
Intervention: Sativex(®) oral spray, up to 12 sprays/day for 12 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo oral spray, up to 12 sprays/day for 12 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sativex(®)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 25874878

Group type: EXPERIMENTAL
Intervention: 12-week cognitive-behavioral lifestyle intervention
Number of subjects: 135

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 135
Study: 23579427

Group type: EXPERIMENTAL
Intervention: High dose alcohol (0.8 g/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low dose alcohol (0.4 g/kg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cognitive alcohol expectancies
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Alcohol dose and outcome expectancies
Number of subjects: 48
Study: 21397257

Group type: EXPERIMENTAL
Intervention: χ‐configuration (group NS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard femoro‐jugular VV‐ECMO (group C)
Number of subjects: 30
Study: 20005375

Group type: EXPERIMENTAL
Intervention: TPN with alanyl‐glutamine (Gln) dipeptide
Number of subjects: 65

Group type: COMPARATOR
Intervention: Traditional TPN support
Number of subjects: 65
Study: 17476012

Group type: EXPERIMENTAL
Intervention: Evaluation and management of superior vena cava syndrome
Number of subjects: 1
Study: 15126724

Group type: EXPERIMENTAL
Intervention: Intervention group (not specified in detail)
Number of subjects: 540
Study: 11202126

Group type: EXPERIMENTAL
Intervention: Coping skills training
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Unspecific supportive control therapy
Number of subjects: 120
Study: 9506598

Group type: EXPERIMENTAL
Intervention: Home rehabilitation (early supported discharge with continuity of rehabilitation at home for 3 to 4 months)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Routine rehabilitation service (hospital, day care, and/or outpatient care)
Number of subjects: 81
Study: 7492128

Group type: EXPERIMENTAL
Intervention: Colchicine, 0.5 mg twice daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Topical emollients (Control)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 41
Study: 2353183

Group type: EXPERIMENTAL
Intervention: Bubble oxygenator
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Membrane oxygenator
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control (thoracotomy without CPB)
Number of subjects: 96
Study: 232697

Group type: EXPERIMENTAL
Intervention: 400 mg pivmecillinam four times daily for seven days
Number of subjects: 100

Group type: COMPARATOR
Intervention: 500 mg ampicillin four times daily for seven days
Number of subjects: 100
Study: 31727676

Group type: EXPERIMENTAL
Intervention: GX-188E injection
Number of subjects: 72
Study: 30632971

Group type: EXPERIMENTAL
Intervention: QuitIT game (along with Standard Care: telecounseling and cessation pharmacotherapies)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard Care (telecounseling and cessation pharmacotherapies)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: QuitIT game
Number of subjects: 42
Study: 28283606

Group type: EXPERIMENTAL
Intervention: rCBV=0.32
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: rCBV=0.34
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: rCBF=0.30
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: rCBF=0.32
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: rCBF=0.34
Number of subjects: 47
Study: 26345179

Group type: EXPERIMENTAL
Intervention: MOMCare (n = 83)
Number of subjects: 168

Group type: COMPARATOR
Intervention: MSS-Plus (n = 85)
Number of subjects: 168
Study: 25927321

Group type: EXPERIMENTAL
Intervention: Genuair (multidose inhaler)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Breezhaler (single-dose inhaler)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Genuair
Number of subjects: 128

Group type: COMPARATOR
Intervention: Breezhaler
Number of subjects: 128
Study: 24252663

Group type: EXPERIMENTAL
Intervention: Videoconference-based CBT
Number of subjects: 26

Group type: COMPARATOR
Intervention: In-person CBT
Number of subjects: 26
Study: 21262317

Group type: EXPERIMENTAL
Intervention: 75 mg caffeine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17693459

Group type: EXPERIMENTAL
Intervention: Thrombolysis (TL)
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (pPCI)
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Thrombolysis (TL) on-site
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Adjusted odds ratio for mortality in women
Number of subjects: 1050
Study: 17139118

Group type: EXPERIMENTAL
Intervention: 11-item pre-interview questionnaire (11-Q)
Number of subjects: 245
Study: 14644398

Group type: EXPERIMENTAL
Intervention: Probucol (500 mg per day)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Pravastatin (10 mg per day)
Number of subjects: 165

Group type: COMPARATOR
Intervention: C. pneumoniae antibody positive patients
Number of subjects: 165

Group type: COMPARATOR
Intervention: Probucol and Pravastatin
Number of subjects: 165
Study: 10723666

Group type: EXPERIMENTAL
Intervention: Single 200 mg dose of levofloxacin (LVFX)
Number of subjects: 56

Group type: COMPARATOR
Intervention: 100 mg of levofloxacin (LVFX) administered twice a day for three days
Number of subjects: 56
Study: 9780939

Group type: EXPERIMENTAL
Intervention: Bilateral sagittal split osteotomy (BSSO)
Number of subjects: 124
Study: 8160955

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 10 micrograms/ml with 0.1% bupivacaine (group FB)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Epidural fentanyl 10 micrograms/ml without bupivacaine (group F)
Number of subjects: 90
Study: 3046646

Group type: EXPERIMENTAL
Intervention: Epoprostenol (prostacyclin)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Tolazoline
Number of subjects: 11
Study: 30075133

Group type: EXPERIMENTAL
Intervention: Hybrid arch bars
Number of subjects: 50

Group type: COMPARATOR
Intervention: Erich arch bars
Number of subjects: 50
Study: 28393428

Group type: EXPERIMENTAL
Intervention: Anaesthesia-Web
Number of subjects: 125

Group type: COMPARATOR
Intervention: Brochure material
Number of subjects: 125
Study: 26140524

Group type: EXPERIMENTAL
Intervention: Perampanel 8 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perampanel 12 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 0
Study: 24172555

Group type: EXPERIMENTAL
Intervention: iCare tonometer
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Pulsair tonometer
Number of subjects: 83

Group type: COMPARATOR
Intervention: Perkins tonometer
Number of subjects: 83
Study: 21177297

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 18329627

Group type: EXPERIMENTAL
Intervention: Goldmann tonometry (GAT)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Pneumatonometry
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Dynamic contour tonometry (DCT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Pneumatonometry vs DCT
Number of subjects: 38

Group type: COMPARATOR
Intervention: Correlation between IOP and corneal thickness
Number of subjects: 38
Study: 16595614

Group type: EXPERIMENTAL
Intervention: Gabapentin 1,600 mg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 14609606

Group type: EXPERIMENTAL
Intervention: LDL cholesterol <70 mg/dl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statin therapy with LDL cholesterol <100 mg/dl
Number of subjects: 0
Study: 10898416

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thrombocytopenia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pseudothrombocytopenia
Number of subjects: 0
Study: 8769601

Group type: EXPERIMENTAL
Intervention: RSHZ19 (0.025‐10.0 mg/kg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: RSHZ19 (10 mg/kg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: RSHZ19 (5 mg/kg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 8311368

Group type: EXPERIMENTAL
Intervention: Current smoking (20 or more cigarettes daily)
Number of subjects: 22071

Group type: EXPERIMENTAL
Intervention: Current smoking (fewer than 20 cigarettes daily)
Number of subjects: 22071

Group type: EXPERIMENTAL
Intervention: Former smoking
Number of subjects: 22071

Group type: COMPARATOR
Intervention: Never-smokers (reference group)
Number of subjects: 22071

Group type: EXPERIMENTAL
Intervention: Total fatal stroke
Number of subjects: 22071
Study: 2905133

Group type: COMPARATOR
Intervention: 20 mg temazepam (Planum)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 29697011

Group type: EXPERIMENTAL
Intervention: Vibralung (PEP and sound)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Vibralung (PEP only)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Vibralung
Number of subjects: 21

Group type: COMPARATOR
Intervention: Vibratory vest therapy (Vest)
Number of subjects: 21
Study: 27739142

Group type: EXPERIMENTAL
Intervention: 4% lidocaine
Number of subjects: 77

Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 77
Study: 26284918

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 31

Group type: COMPARATOR
Intervention: Insulin Glargine
Number of subjects: 31
Study: 23471469

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 850
Study: 20964769

Group type: COMPARATOR
Intervention: Acetaminophen alone (40 mg·kg(‐1) rectal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetaminophen and intranasal fentanyl (1 mcg·kg(‐1))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetaminophen and intramuscular ketorolac (1 mg·kg(‐1))
Number of subjects: 0
Study: 18211600

Group type: EXPERIMENTAL
Intervention: Feminine pads with absorbent gelling material
Number of subjects: 0

Group type: COMPARATOR
Intervention: Feminine pads with cellulose absorbent cores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical in-use study with feminine pads
Number of subjects: 0
Study: 17012138

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 14524005

Group type: EXPERIMENTAL
Intervention: Gm allotypes
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Km allotypes
Number of subjects: 133
Study: 10740141

Group type: EXPERIMENTAL
Intervention: Candesartan (initial dosage 4 mg/d, increased to 16 mg/d if tolerated)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 270
Study: 8715233

Group type: EXPERIMENTAL
Intervention: Prenatal group educational sessions emphasizing skills necessary to initiate and maintain breastfeeding
Number of subjects: 59

Group type: COMPARATOR
Intervention: Five basic interventions (control group)
Number of subjects: 59
Study: 1376362

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.5-8.0 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hydromorphone (5 and 10 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Naloxone (0.1 and 0.2 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6
Study: 6722464

Group type: EXPERIMENTAL
Intervention: Subcutaneous sphincterotomy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Open sphincterotomy
Number of subjects: 28
Study: 29850956

Group type: EXPERIMENTAL
Intervention: PEKK-made crowns and bridges (Pekkton ivory)
Number of subjects: 22

Group type: COMPARATOR
Intervention: CoCr-made crowns
Number of subjects: 22
Study: 30043449

Group type: EXPERIMENTAL
Intervention: SQ house dust mite sublingual immunotherapy-tablet (10,000 JAU)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study: 26897452

Group type: EXPERIMENTAL
Intervention: Jaw closure using an air-inflatable pneumatic actuator at 6-cm head elevation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Neutral occlusion at 6-cm head elevation
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Jaw closure at 0-cm head elevation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Neutral occlusion at 0-cm head elevation
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Jaw closure at 6-cm head elevation
Number of subjects: 6
Study: 25280421

Group type: EXPERIMENTAL
Intervention: Zinc acetate preparation at a dose of 3 capsules/d for a total zinc content of 150 mg/d (Z group)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (P group)
Number of subjects: 12
Study: 22850072

Group type: EXPERIMENTAL
Intervention: Standard 4-drug therapy (Metronidazole 500 mg/BD, Amoxicillin 1g/BD, Omeprazole 20mg/BD, Bismuth 240 mg/BD) + Lycopene (30 mg/daily)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard 4-drug therapy (Metronidazole 500 mg/BD, Amoxicillin 1g/BD, Omeprazole 20mg/BD, Bismuth 240 mg/BD)
Number of subjects: 54
Study: 19549250

Group type: EXPERIMENTAL
Intervention: Insulin-glucose infusion therapy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 55
Study: 17906340

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting Cypher stents
Number of subjects: 350

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 350
Study: 15588161

Group type: EXPERIMENTAL
Intervention: Resection of colorectal cancer
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gastric banding
Number of subjects: 20
Study: 12046701

Group type: EXPERIMENTAL
Intervention: Nonlinear Wiener model of pure seizure activity
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Nonlinear Wiener model of pure background activity
Number of subjects: 64

Group type: COMPARATOR
Intervention: Roessgen model
Number of subjects: 64
Study: 10442414

Group type: EXPERIMENTAL
Intervention: Pro-saccade (0 degrees)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-saccade (30, 60, 90, 120, 150, 180 degrees)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peripheral cues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Central cues
Number of subjects: 0
Study: 7842769

Group type: EXPERIMENTAL
Intervention: Bambuterol (20 mg tablet) - morning administration
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Bambuterol (20 mg tablet) - evening administration
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 2297349

Group type: EXPERIMENTAL
Intervention: Fish oil (3.8 g of n-3 fatty acids)
Number of subjects: 33
Study: 7002197

Group type: EXPERIMENTAL
Intervention: peroral zinc sulphate
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 31815641

Group type: EXPERIMENTAL
Intervention: Mild hypothermia (32 °C)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Moderate hypothermia (26 °C)
Number of subjects: 282
Study: 27854382

Group type: EXPERIMENTAL
Intervention: CTG-STV (reduced fetal heart rate short-term variation)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: DV-p95 (early changes in fetal ductus venosus waveform)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: DV-no-A (late changes in fetal ductus venosus waveform)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Safety-net criteria (spontaneous decelerations in FHR)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Maternal reasons for delivery
Number of subjects: 310
Study: 25840512

Group type: EXPERIMENTAL
Intervention: Open reduction internal fixation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Closed reduction
Number of subjects: 50
Study: 24007456

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg once daily (qd)
Number of subjects: 1549

Group type: COMPARATOR
Intervention: Glimepiride 1-4 mg qd
Number of subjects: 1549
Study: 21309914

Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lugol chromo-endoscopy
Number of subjects: 30

Group type: COMPARATOR
Intervention: White light
Number of subjects: 30
Study: 19389416

Group type: EXPERIMENTAL
Intervention: Induction pulse with increased contrast or dot density
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induction pulse with varying strength
Number of subjects: 0
Study: 16677064

Group type: EXPERIMENTAL
Intervention: Peer support intervention (legal/financial training session followed by five small-group workshops)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 15841998

Group type: EXPERIMENTAL
Intervention: Intranasal endoscopic sphenopalatine artery ligation (ESAL)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional nasal packing (Merocel)
Number of subjects: 19
Study: 11368130

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/day
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 9402071

Group type: EXPERIMENTAL
Intervention: Nucleoside (zidovudine 600 mg/day and zalcitabine 2.25 mg/day)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 1-mIU interferon-alpha2a
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 6-mIU interferon-alpha2a
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Nucleoside + 1-mIU interferon
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Nucleoside + 6-mIU interferon
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 63
Study: 8214960

Group type: EXPERIMENTAL
Intervention: Nasogastric decompression maintained postoperatively until resumption of bowel function (Group 1)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Nasogastric tube removed in the recovery room (Group 2)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Group 1
Number of subjects: 77

Group type: COMPARATOR
Intervention: Group 2
Number of subjects: 77
Study: 3659583

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (30 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Dextromethorphan + Salbutamol (30 mg + 2 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 29677619

Group type: EXPERIMENTAL
Intervention: Childhood adversities
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Parental problems
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Recollected family unhappiness
Number of subjects: 221
Study: 27207493

Group type: EXPERIMENTAL
Intervention: Local cold gel pack
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Local cold-hot gel pack
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study: 25049242

Group type: EXPERIMENTAL
Intervention: DHA-PQ with 8.5 g fat (group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: DHA-PQ without fat (group A)
Number of subjects: 30
Study: 22946930

Group type: EXPERIMENTAL
Intervention: i.v. ibandronate 3 mg every 3 months for 12 months
Number of subjects: 129

Group type: COMPARATOR
Intervention: i.v. placebo every 3 months for 12 months
Number of subjects: 129
Study: 20012857

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 218

Group type: COMPARATOR
Intervention: No exercise (control)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Combined exercise
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 218
Study: 18940086

Group type: EXPERIMENTAL
Intervention: Listening to a radio transmission (oral medium)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reading a transcription of a radio transmission (written medium)
Number of subjects: 0
Study: 17217107

Group type: EXPERIMENTAL
Intervention: Open hemorrhoidectomy for stage II hemorrhoidal disease
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Closed hemorrhoidectomy for stage III hemorrhoidal disease
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Long's method (stapling device) for stage III hemorrhoidal disease
Number of subjects: 97
Study: 12888874

Group type: EXPERIMENTAL
Intervention: Enoxaparin (subcutaneous, twice daily)
Number of subjects: 68

Group type: COMPARATOR
Intervention: UFH (intravenous)
Number of subjects: 68
Study: 10981841

Group type: EXPERIMENTAL
Intervention: Loss of majority position (majority-to-minority change)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Gain of majority position (minority-to-majority change)
Number of subjects: 2
Study: 9368703

Group type: EXPERIMENTAL
Intervention: 100 mg acarbose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 100 mg acarbose plus 10 ml antacid suspension
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10 ml antacid suspension
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1334819

Group type: EXPERIMENTAL
Intervention: Higher proportion of eligible patients cared for by medical staff other than private attending physicians
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Presence of a nurse coordinator at the site
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Number of nurse coordinator full-time equivalents at the site
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Fewer other clinical trials for which the nurse coordinator was responsible
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Fewer perceived obstacles to enrollment
Number of subjects: 112
Study: 3887887

Group type: EXPERIMENTAL
Intervention: 500 g naturally labeled 13C carbohydrate after high fat antecedent diet
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 500 g naturally labeled 13C carbohydrate after mixed antecedent diet
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 500 g naturally labeled 13C carbohydrate after high carbohydrate antecedent diet
Number of subjects: 14
Study: 28738709

Group type: EXPERIMENTAL
Intervention: Nebulized hypertonic saline solution (HSS) twice daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group with VAP prevention protocol
Number of subjects: 100